QCM Cayman’s TherapeuticsMD TXMD Stock Holding History

QCM Cayman’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-230	Closed	-$69K	–	183
2017 Q4	$69K	Buy	+230	New	+$64K	0.29%	96

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM Cayman's TXMD Position: Q1 2018 in Review

QCM Cayman sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 230 shares — an estimated $69K sold.

QCM Cayman first reported a position in TXMD in Q4 2017 and held it in 1 quarter. The position peaked at $69K in Q4 2017. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

QCM Cayman reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
QCM Cayman sold 230 TherapeuticsMD shares in Q1 2018, an estimated $69K.
QCM Cayman first reported a position in TherapeuticsMD in Q4 2017 and held it in 1 quarter.
QCM Cayman's TherapeuticsMD position peaked at $69K in Q4 2017.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on QCM Cayman's 13F filing for Q1 2018, filed 15 May 2018.